Grant✓ Small businesses may apply
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-25-070
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.393
- Status
- posted
- Posted
- Nov 18, 2024
- Closes
- Jan 7, 2027
- Funding instrument
- Grant
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •State governments
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •County governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Public and State controlled institutions of higher education
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •Private institutions of higher education
- •Special district governments
- •Small businesses
- •Independent school districts
- •City or township governments
- •Native American tribal governments (Federally recognized)
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Contact
National Institutes of Health · grantsinfo@nih.gov